title: Reply to R.L. Nussbaum et al and J.S. Dolinsky et al.
authors.affiliation: Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
authors.forename: Judith
authors.initials: J
authors.lastname: Balmaña
authors.affiliation: Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Nathanson
authors.affiliation: Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Offit
authors.affiliation: Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
authors.forename: Mark
authors.initials: M
authors.lastname: Robson
authors.affiliation: Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
authors.forename: Susan
authors.initials: S
authors.lastname: Domchek
mesh_terms: D006801:Humans; D011446:Prospective Studies; D011471:Prostatic Neoplasms; D012042:Registries; D012306:Risk